Albireo Pharma, Inc.
Albireo Pharma, Inc. (ALBO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
albo · stock forecast · 12 analysts (3M) · FMP · updated Dec 4, 2023
Analyst Rating & Consensus
Based on 12 Wall Street analysts in the past 3 months
Buy
12 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$48.00
Consensus
$44.00
-0.3% upside
Low
$42.00
Median: $42 · Last Close: $44.15
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$44.00
-0.3% upside
High Target
$48
8.7%
Low Target
$42
-4.9%
Current Price
$44.15
as of today
Based on analyst price targets, the ALBO stock price prediction for the next 12 months ranges from $42 to $48. The consensus ALBO price forecast of $44.00 implies -0.3% upside from the current price of $44.15.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $44.16 | ↑ 0.01% |
1-day model range: $44.11–$44.2. Peak: $44.2 (+0.01%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ALBO · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-02-15 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2023-01-11 | Cowen & Co. | Downgrade ↓ | Outperform→Perform |
| 2023-01-11 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2023-01-11 | Guggenheim | Downgrade ↓ | Buy→Neutral |
| 2023-01-10 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2023-01-09 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2022-10-13 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-10-12 | Baird | Maintains | Outperform→Outperform |
| 2022-09-08 | Guggenheim | Maintains | Buy→Buy |
| 2022-08-16 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Albireo Pharma, Inc. (ALBO) stock. Of the recent 33 rating actions, 0 were upgrades and 5 were downgrades. 12 analysts currently cover ALBO.
Analyst Recommendation Trends
ALBO analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast ALBO EPS of $— for the current fiscal year, based on estimates from 0 analysts. The ALBO revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ALBO stock forecast is supported by two independent data sources: analyst consensus ratings from 12 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ALBO price target is $44.00 (-0.3% upside), with an analyst consensus of Buy.
The ALBO short-term stock prediction for tomorrow is $44.16 (+0.01%).
Albireo Pharma, Inc. trades on NASDAQ under the ticker ALBO. The ALBO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 58% of covering analysts.
Frequently asked questions
ALBO forecast · 8 questionsAccording to 12 Wall Street analysts, the average 12-month ALBO price target is $44.00, with a high forecast of $48.00 and a low of $42.00. The median price target is shown in the chart above when available. This implies -0.3% potential upside from the current price of $44.15.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.